Explore
Respiratory Disease in the COVID-19 Era
0 Ungluers have
Faved this Work
Login to Fave
Coronavirus disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused a global pandemic. COVID-19 patients often develop acute respiratory distress syndrome (ARDS), which involves acute and lethal respiratory failure. In a meta-analysis, the median incidence of ARDS in COVID-19 patients was found to be 35 (2-79)%, while the mortality rate in COVID-19-associated ARDS patients was found to be 39 (12.5-73.1)% (Hasan, et al. Expert Rev Repoir Med. 2020; 14: 1149). As of 12 December 2021, 270,373,764 cases had been confirmed as COVID-19 and 5,321,321 cases had resulted in death, according to the World Health Organization webpage. Various symptoms such as persistent fatigue, myalgia, and insomnia can persist after recovery from COVID-19; these symptoms are called “long COVID-19”. Patients with COVID-19 who survive but develop pulmonary fibrosis may experience persistent dyspnea upon exertion, a decrease in pulmonary function, and/or a radiological abnormal shadow. Antifibrotic drugs including nintedanib and pirfenidone are candidate drugs for the treatment of pulmonary fibrosis due to COVID-19; randomized controlled trials are ongoing. However, there are limited studies about respiratory disease caused by COVID-19. Given the clinical significance of this topic and its impact on clinical practice and public health, Medicina have published a Special Issue entitled “Respiratory Disease in the COVID-19 Era” with the aim of gathering accurate and up-to-date scientific information of this topic.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 24 times via unglue.it ebook links.
- 24 - pdf (CC BY) at Unglue.it.
Keywords
- adult
- ARDS
- Bamlanivimab
- Bruton’s tyrosine kinase
- case cluster
- computed tomographic severity score
- coronavirus disease 2019
- COVID-19
- COVID-19 vaccines
- delayed diagnosis
- Diabetes Mellitus
- diaphragm
- Epidemiology & medical statistics
- Etesevimab
- Heart Rate
- HRCT
- hydroxychloroquine
- immunocompromised
- immunocompromised host
- immunosuppressive drugs
- inflammatory markers
- interstitial pneumonia
- lung ultrasound
- medicine
- Medicine: General Issues
- n/a
- Paragonimus westermani
- persistent infection
- Pneumocystis jirovecii pneumonia
- Pneumonia
- post-COVID-19 condition
- Public health & preventive medicine
- pulmonary paragonimiasis
- pulmonary rehabilitation
- respiratory function
- Risk
- RT-qPCR
- SARS-CoV-2
- Severe Acute Respiratory Syndrome
- spontaneous pneumomediastinum
- Steroids
- subcutaneous emphysema
- Survival
- therapeutic plasma exchange
- thoracic mobilization
Links
DOI: 10.3390/books978-3-0365-7917-7Editions